Drugs / SH3765
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07557004 | Sep 2025 → Jun 2027 expected | hormone receptor-positive breast cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05015309 | Sep 2021 → Mar 2023 | cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH3765 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557004 ↗ |
| Action | Inhibit | “PRMT5 inhibitor” NCT05015309 ↗ |
| Route | Oral | “oral administered once daily” NCT05015309 ↗ |
| Target | PRMT5 | “PRMT5” NCT05015309 ↗ |